Exploring the Impact of Guselkumab and Risankizumab on Psoriasis in <scp>HIV</scp>‐Positive Patients: Insights From Four Italian Centers
HIV-positive patients with psoriasis often face delays in accessing biologic therapies due to their exclusion from clinical trials and concerns about the impact of immunomodulatory drugs on viral replication. Anti-IL-23 therapies, such as risankizumab and guselkumab, have shown great promise thanks to their strong efficacy and favourable safety profiles. A case series from four Italian centres reported sustained effectiveness of these drugs, with no observed effects on viral replication or immune parameters in HIV-positive patients. Although the number of cases is limited, these therapies appear to be a compelling option for patients with extensive or treatment-resistant psoriasis.
Authors
- Francesco Bellinato (ORCID: https://orcid.org/0000-0002-6163-6921)
- Claudio Romano (ORCID: https://orcid.org/0000-0001-8827-2091)
- Enzo Errichetti (ORCID: https://orcid.org/0000-0002-7152-6136)
- Zeno Fratton (ORCID: https://orcid.org/0000-0002-7454-1999)
- Vincenzo Maione (ORCID: https://orcid.org/0000-0002-0420-5009)
- Stefano Bighetti (ORCID: https://orcid.org/0009-0006-2781-6909)
- S. Rovaris
- Mariachiara Arisi (ORCID: https://orcid.org/0000-0001-6307-6174)
- Luca Bettolini (ORCID: https://orcid.org/0000-0003-4374-802X)
- Paolo Gisondi (ORCID: https://orcid.org/0000-0002-1777-9001)
- Carlo Giovanni Carrera
Institutions
- University of Verona (IT)
- University of Udine (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Brescia (IT)
Publication Details
- Journal
- Australasian Journal of Dermatology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1111/ajd.14467
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80